Company
We exclusively distribute high-quality oncological drugs and special therapeutics, which are subject to strict quality controls.
Team
We see the culture at Bendalis as a competitive advantage and strive to create an environment where intelligent, motivated, and creative people can thrive.
Behind our products, solutions, and services is a team of professionals with extensive experience and knowledge in the pharmaceutical sector. Our employees are dedicated team players, bringing energy, ideas and pride to their work.
Since 1 October 2021, Dr Wolfgang Burger has taken over the management. Dr Burger has over 30 years of experience in the pharmaceutical industry, most recently as Managing Director of PharmaZell GmbH.
With effect from 1st April 2022, Dr. Dirk Hütten has joined Mr. Dr. Burger on the management board. Dr. Hütten has over 20 years of experience in various international sales roles along the pharmaceutical product supply chain.
Milestones
Year of establishment of Bendalis GmbH, based in Oberhaching near Munich.
2006
Launch of Bendafolin® (folinic acid).
2007
Launch of five oncology products:
- 5-Fluorouracil (5-FU)
- Carboplatin
- Doxorubicin
- Methotrexate
- Paclitaxel
2008
Collaboration with EUSA Pharma GmbH in the distribution of Caphosol® for the treatment of oral mucositis.
Expansion of the product portfolio with six generic cancer drugs.
- Epirubicin
- Gemcitabine
- Irinotecan
- Octreotide
- Oxaliplatin
- Vinorelbine
2009
Collaboration with Riemser Arzneimittel AG for the distribution of ALOXI®, an innovative 5-HT3 receptor antagonist for the prophylaxis of chemotherapy-induced nausea and vomiting.
Expansion of the product portfolio to include the supportive care product line, AgainLife Italia:
- OraLife – Mouth and Throat
- TraLife – Oral Cavity
- RaLife – Top
- EvaLife – Intimate Area
- GutLife – Anal Area
2011
Expansion of the product portfolio with two generic cancer medications:
- Zoledronic acid
- Ibandronic acid
2013
Expansion of the Supportive Care Product Portfolio: KapDolen 30 ml – for the relief of damaged tissues and nerve fibres.
2016
Expansion of the Supportive Care Product Portfolio: KapDolen 100 ml – for the relief of damaged tissues and nerve fibres.
2017
Inceptua and Bendalis conclude exclusive agreement for clinical studies of oncology drugs.
2019
Bendalis acquires Sugammadex and worldwide distribution rights from Biofactor GmbH.
2025
5FU and Vancomycin back in stock – new European manufacturing capacity by Bendalis ensures supply.
2026
Quality Management
We will gladly provide you with information on our quality policy upon request.
Bendalis GmbH places great importance on quality.
With GMP and GDP certification, as well as a manufacturing and wholesale license, we meet all expectations for the production and distribution of our products.
Our customers can rely on the quality standards of Bendalis GmbH.
Our Commitment
The well-being of patients guides our actions. As a manufacturer of life-saving medicines, we see it as our duty to ensure a reliable supply – especially in challenging times.
How we put patients at the centre:
- Investments in stable supply chains and dual active ingredient procurement
- Production within the EU to the highest quality and safety standards
- Close cooperation with professional circles and research for optimum results
- Open communication regarding supply shortages
- Continuous further development and consideration of feedback from practice and the patient community
Bendalis – For the well-being of patients.
Our sister company Lyomark Pharma GmbH – founded in 1989 in Oberhaching near Munich as a contract and active ingredient manufacturer for niche products. Lyomark is a service provider for lyophilised and liquid sterile products and has established itself in this field within the pharmaceutical industry for over 25 years.
In addition to manufacturing, services include the provision and maintenance of dossiers and the submission of national and international authorisations for well-known pharmaceutical companies.
